1832 Asset Management
TGTX icon

1832 Asset Management’s TG Therapeutics TGTX Stock Holding History

1832 Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
+186,300
New +$7.62M 0.01% 364
2025
Q3 		– Sell
-144,000
Closed -$5.18M – 714
2025
Q2 		$5.18M Sell
144,000
-1,339,800
-90% -$49.9M ﹤0.01% 372
2025
Q1 		$58.5M Sell
1,483,800
-171,300
-10% -$5.76M 0.05% 176
2024
Q4 		$49.8M Buy
+1,655,100
New +$47.5M 0.04% 185

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

1832 Asset Management's TGTX Position: Q2 2026 in Review

1832 Asset Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 186,300 shares worth $10.2M. The stake represents 0.01% of the portfolio and ranks #364 among its holdings. This is a return to the name: 1832 Asset Management previously reported a position in TGTX as recently as Q2 2025.

1832 Asset Management first reported a position in TGTX in Q4 2024 and has held it in 4 quarters since. The position peaked at $58.5M in Q1 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • 1832 Asset Management held 186,300 shares of TG Therapeutics worth $10.2M as of Q2 2026.
  • TG Therapeutics was a new 1832 Asset Management position in Q2 2026.
  • TG Therapeutics made up 0.01% of 1832 Asset Management's portfolio in Q2 2026, its #364 holding.
  • 1832 Asset Management first reported a position in TG Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 1832 Asset Management's TG Therapeutics position peaked at $58.5M in Q1 2025.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on 1832 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.